CoChat

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo

Open access

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is a complex and widespread condition, still not fully understood and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by inhibition of the enzymes BACE-1 (β-secretase) and AChE (acetylcholinesterase) by a single inhibitor may be an effective therapeutic approach, as compared to blocking one of these targets or by combining two drugs, one for each of these targets. We used our ISE algorithm to model each of the AChE peripheral site inhibitors and BACE-1 inhibitors, on the basis of published data, and constructed classification models for each. Subsequently, we screened large molecular databases with both models. Top scored molecules were docked into AChE and BACE-1 crystal structures, and 36 Molecules with the best weighted scores (based on ISE indexes and docking results) were sent for inhibition studies on the two enzymes. Two of them inhibited both AChE (IC50 between 4–7 μM) and BACE-1 (IC50 between 50–65 μM). Two additional molecules inhibited only AChE, and another two molecules inhibited only BACE-1. Preliminary testing of inhibition by F681-0222 (molecule 2) on APPswe/PS1dE9 transgenic mice shows a reduction in brain tissue of soluble Aβ42.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232113098

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A MT (multi-targeted) drug could bind to both targets, BACE-1 (pink colored) and AChE (violet colored), so the two processes: Aβ peptide (green colored) formation from APP and Aβ aggregation. would be blocked. Additionally, by blocking AChE in the PAS, the level of non-hydrolyzed acetylcholine neurotransmitter would rise, thus, improving cholinergic activity simultaneously with the reduction in aggregation. The protein illustrations were made with Pymol software, Schrödinger and the PDB structure codes: 4M0F (AChE), 4DJW (BACE-1) and 1IYT (Aβ42).
Figure 1 A MT (multi-targeted) drug could bind to both targets, BACE-1 (pink colored) and AChE (violet colored), so the two processes: Aβ peptide (green colored) formation from APP and Aβ aggregation. would be blocked. Additionally, by blocking AChE in the PAS, the level of non-hydrolyzed acetylcholine neurotransmitter would rise, thus, improving cholinergic activity simultaneously with the reduction in aggregation. The protein illustrations were made with Pymol software, Schrödinger and the PDB structure codes: 4M0F (AChE), 4DJW (BACE-1) and 1IYT (Aβ42).CC BY · PubMed Central
Figure 2 Research workflow: After the creation of ISE models for AChE and for BACE-1, large databases (Section 1.4) were screened by the models’ filters and 682 molecules had top scores in both. These molecules were docked by FlexX and were given weighted scores based on both the docking results and on ISE indexes (Supplementary Excel File, Table S10E). The 177 molecules with the highest weighted scores (Supplementary Excel File, Table S14E) were filtered again by calculated logP and visual inspection to obtain the final 66 molecules (Supplementary Excel File, Table S15E) of which 36 were purchased and sent for testing inhibitions of AChE and of BACE-1 (Supplementary Excel File, Table S16E). Six molecules inhibited either AChE or BACE-1, and two of them inhibited both enzymes (Supplementary Excel File, Table S17E). Details of the in vitro tests are given in Section 2.4 below and the results are presented in Supplementary Excel File, Tables S16E and S17E.
Figure 2 Research workflow: After the creation of ISE models for AChE and for BACE-1, large databases (Section 1.4) were screened by the models’ filters and 682 molecules had top scores in both. These molecules were docked by FlexX and were given weighted scores based on both the docking results and on ISE indexes (Supplementary Excel File, Table S10E). The 177 molecules with the highest weighted scores (Supplementary Excel File, Table S14E) were filtered again by calculated logP and visual inspection to obtain the final 66 molecules (Supplementary Excel File, Table S15E) of which 36 were purchased and sent for testing inhibitions of AChE and of BACE-1 (Supplementary Excel File, Table S16E). Six molecules inhibited either AChE or BACE-1, and two of them inhibited both enzymes (Supplementary Excel File, Table S17E). Details of the in vitro tests are given in Section 2.4 below and the results are presented in Supplementary Excel File, Tables S16E and S17E.CC BY · PubMed Central
Figure 3 BACE-1 superimposed structures 2G94 (cyan) and 4DJW (pink) in closed and open conformations, respectively. (A) the whole enzyme. (B) An enlargement of the flap region with its residues that have the largest RMSD values (these are the same residues, but with different numbering in PDB structures 70–73 or 131–134). (C) ligands in the binding site: 2G94 peptidomimetic ligand in light blue, 4DJW aminohydantoin ligand in pink. The illustration was made with Maestro 11.0, Schrödinger.
Figure 3 BACE-1 superimposed structures 2G94 (cyan) and 4DJW (pink) in closed and open conformations, respectively. (A) the whole enzyme. (B) An enlargement of the flap region with its residues that have the largest RMSD values (these are the same residues, but with different numbering in PDB structures 70–73 or 131–134). (C) ligands in the binding site: 2G94 peptidomimetic ligand in light blue, 4DJW aminohydantoin ligand in pink. The illustration was made with Maestro 11.0, Schrödinger.CC BY · PubMed Central
Figure 4 The six hit compounds.
Figure 4 The six hit compounds.CC BY · PubMed Central
Figure 5 Decrease in Aβ42 level in the brains of mice. In blue—control TG = transgene mice; In orange—tested compound, 2.
Figure 5 Decrease in Aβ42 level in the brains of mice. In blue—control TG = transgene mice; In orange—tested compound, 2.CC BY · PubMed Central
Figure 6 (A) The interactions of the dual hit, 3, (F681-0412), with binding site residues in AChE (created with MOE2011). All the important AChE residues are present and in close contacts with the ligand. Non-polar residues are colored green, polar residues are colored light purple, acidic residues are further annotated by a red ring. A hydrogen bond is marked with an arrow, and aromatic hydrocarbon interactions with H atom or a cation are marked as well. In addition to the H-bonds shown by arrows, the other residues interact with the ligand by VdW atom–atom interactions. Most of the residues mentioned in Section 2.2.5 and Supplementary Word File, Section 1.10, are shown in this figure. (B) A corresponding 3D pose of hit 3.
Figure 6 (A) The interactions of the dual hit, 3, (F681-0412), with binding site residues in AChE (created with MOE2011). All the important AChE residues are present and in close contacts with the ligand. Non-polar residues are colored green, polar residues are colored light purple, acidic residues are further annotated by a red ring. A hydrogen bond is marked with an arrow, and aromatic hydrocarbon interactions with H atom or a cation are marked as well. In addition to the H-bonds shown by arrows, the other residues interact with the ligand by VdW atom–atom interactions. Most of the residues mentioned in Section 2.2.5 and Supplementary Word File, Section 1.10, are shown in this figure. (B) A corresponding 3D pose of hit 3.CC BY · PubMed Central
Figure 7 The interactions of hit molecule 2 with binding site residues of BACE-1 Asp93 deprotonated structure. Both of the catalytic aspartates form hydrogen bonds with the hit molecule.
Figure 7 The interactions of hit molecule 2 with binding site residues of BACE-1 Asp93 deprotonated structure. Both of the catalytic aspartates form hydrogen bonds with the hit molecule.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Research works printed but not linked: 1

  1. Deng, 2016, Design, Synthesize and Bio-Evaluate 1,2-Dihydroisoquinolin-3(4H)-One Derivates as Acetylcholinesterase and β-Secretase Dual Inhibitors in Treatment with Alzheimer’s Disease, J. Biosci. Med., 4, 112

Cited by

See all 37

Metadata

Authors
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., Kígyós, A., Tóvári, J., & Goldblum, A.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • National Institute of Oncology (HU)
  • TargetEx Ltd., H-2120 Dunakeszi, Hungary
  • Institute of Molecular Life Sciences (HU)
  • KINETO Lab Ltd., H-1032 Budapest, Hungary
  • Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Corresponding author
Goldblum, Amiram
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-10-28
Volume
23
Issue
21
Pages
13098
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4307945532
Cited by
35
References
92
Citations by year
2026: 12 · 2025: 8 · 2024: 8 · 2023: 7
FWCI
3.44
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
the Research and Technology Innovation Fund (EUREKA_HU_12-1-2012-0057)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
Alzheimer's disease, amyloid-beta, acetylcholinesterase inhibitors, BACE1 inhibitors, dual enzyme inhibition, virtual screening, molecular docking, enzyme inhibition, APP/PS1 mice
MeSH terms
Acetylcholinesterase, Alzheimer Disease, Animals, Brain, Cholinesterase Inhibitors, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo. https://app.cochat.ai/papers/10.3390/ijms232113098
The paper
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., Kígyós, A., Tóvári, J., & Goldblum, A. (2022). Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232113098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.